Pulmonary edema in parturient can be because of various reasons. Parturients are at risk of pulmonary edema because of the physiological changes. Here, we report successful management of a case of pulmonary edema caused by prostodin (Carboprost) given within a maximal dose limit. Prostodin acts as a smooth muscle stimulant and is a recognized second-line agent for use in the management of postpartum uterine atony unresponsive to oxytocin/ergometrine. It may induce pulmonary edema but rare in limited doses. However, vigilant monitoring and timely intensive care management helped us successfully to manage the case.
INTRODUCTION
A 28-year-old lady, G2P1Lo at her 37th weeks of gestation, was taken up for emergency cesarean section for fetal distress with bleeding PV. Blood sugar was under control. Her preoperative investigations were within normal limits. Informed consent was obtained after explaining all anesthetic concerns to the patient and her relatives.
In the preoperative area, she was conscious, oriented with blood pressure 90/54 mm Hg, pulse rate 112/min, and oxygen saturation 100% on FM with O 2 @ 6 LPM. As she was actively bleeding through per vaginum two 16 G IV cannula were inserted and fluid started. In view of acute fetal distress, it was decided to administer general anesthesia for the cesarean section. She was preoxygenated with 100% O 2 for 3 minutes and rapid sequence intravenous induction performed with 100 mg ketamine, 100 mg succinylcholine, patient was intubated with 7 mm ID ET tube using Sellick's maneuver. Anesthesia was maintained with O 2 , isoflurane along with vecuronium bromide. After 7 minutes, the baby was delivered after which inhalational agent was reduced to ≤1%. Patient was administered inj fentanyl 100 μg intravenously for analgesia after the baby was delivered. Oxytocin infusion was started at the rate of approximately 0.04 mIU/min. However, the patient went into postpartum hemorrhage (PPH) due to uterine atony, which did not even respond to an increase in the rate of oxytocin infusion. Massaging was started. Inhalation agents were turned off. The patient lost about 1.8 to 2 L of blood. Intraoperatively, the placenta was found to be central-posterior and accreta type. Manual removal of complete placenta was done. Prostaglandin F2-alpha-carboprost trometamol 0.25 mg (Prostodin, AstraZeneca, India). Single dose of prostodin was not so helpful, so subsequent one more dose was administered (after 10-15 minutes). Two and half liters crystalloids and one PC were transfused. Mean arterial pressure maintained above 65 mm Hg. Meanwhile, PPH was controlled and the uterine closure was started. As the skin incision was closed, a trend in rise of peak airway pressure and SpO 2 drop was observed by the anesthesiologist. Auscultation revealed B/L crepitations. Provisional diagnosis of acute pulmonary edema was made and immediately injection frusemide 40 mg and injection morphine 4.5 mg was administered IV. Intraoperatively, fluid administered was 1000 ml crystalloid.
Neuromuscular blockade was not reversed and the patient was shifted to intensive care unit (ICU) for further management. Postoperative electrocardiogram did not reveal any fresh changes but chest X-ray was suggestive of pulmonary edema ( Fig. 1 ) and was also confirmed by ultrasound. In ICU, patient was immediately put on Vigileo hemodynamic monitoring (EV 1000, Edwards Lifesciences, United States) which revealed a high systemic vascular resistance (SVR), and a low stroke volume (SV), a low normal cardiac index (CI) and excess extravascular lung water (EVLW). Infusion dobutamine was started @ 5 mcg/kg/min. Systemic vascular resistance reduced gradually with improvement in SV and CI. Injection frusemide 40 mg and morphine 4.5 mg was repeated. Echocardiography (ECHO) heart was asked for which revealed trace mitral regurgitation, trace tricuspid regurgitation and no other abnormalities. Chest was clear after 6 hours ( Figs 1A and B) . It was also evidenced by auscultation, chest X-ray, EVLW. PaO 2 /FiO 2 was 326. Patient was successfully extubated subsequently and kept on FM with O 2 @ 5 LPM in a propped up position and gradually weaned off from O 2 .
DISCUSSION
Prostodin [15-methyl prostaglandin (PG) F2-alpha, Astra Zeneca Pharma, London] acts as a smooth muscle stimulant and is a recognized second-line agent for use in the management of postpartum uterine atony unresponsive to oxytocin/ergometrine. It is an analog of PG F2-alpha (dinoprost) with a longer duration of action than its parent compound, attributed to its resistance to inactivation by oxidation at the 15-position. Available in single-dose vials of 0.25 mg, it may be administered by deep intramuscular injection or, alternatively, by direct intramyometrial injection. The latter route of administration is achieved either under direct vision at cesarean section or transabdomen or transvaginal following vaginal delivery and has the advantage of a significantly quicker onset of action. Peripheral intramuscular injection yields peak plasma concentrations at 15 minutes in contrast to less than 5 minutes for the intramyometrial route. Side effects of PG F2-alpha are related to its effects on smooth muscles. They include nausea, vomiting, diarrhea, bronchospasm and systemic hypertension. 1 Secher et al 2 found a 40% increase in cardiac output in pregnant anesthetized women during infusion of 300 μg of PG F2-alpha with an increase in pulmonary arterial pressure, doubling of pulmonary vascular resistance and increase in airway resistance.
Cardiovascular collapse along with left heart failure has been reported with overdose of intramyometrial prostodin, the possible etiology being a combination of acute pulmonary hypertension with decreased left ventricular end-diastolic pressure and decreased cardiac output. 3 Rodríguez de la et al 4 reported a case of pulmonary edema related to administration of 15-methylprostaglandin F2-alpha during a cesarean section. After delivery, uterine atony was treated unsuccessfully with oxytocin and methylergometrine maleate; the obstetrician then gave an intramyometrial injection of 0.25 mg of 15-methyl-prostaglandin F2-alpha (PGF2-alpha). After 5 minutes, SpO 2 fell to 89%, accompanied by dyspnea and sinus tachycardia of 130 to 140 beats/min, with normal cardiorespiratory sounds. The patient was transferred to the postoperative recovery unit, where a chest radiograph led to a diagnosis of acute pulmonary edema. In our case, even though the single administration dose of prostaglandin F2-alpha was kept below the maximum dose range the pregnant physiology puts the parturient at risk of pulmonary edema. With no other significant cardiac or respiratory diseases, we can say that prostaglandin F2-alpha induced the sequence of pulmonary edema in our patient. We should be cautious while administering prostaglandin F2-alpha in a suspected PPH patient. 
